Federico Bolognani

Federico Bolognani, MD, PhD, currently serves as the Chief Medical Officer at IAMA Therapeutics and is a member of the Strategic Advisory Board for CureSHANK. As the owner of Catran GmbH and former Vice President and Head of Clinical Development at VectivBio AG, Federico has extensive experience in clinical science, having held key positions at various organizations including Axial Therapeutics, Therachon, Roche Pharmaceuticals, and Novartis. Educational qualifications include a PhD focused on gene therapy of pituitary tumors and an MD from Universidad Nacional de La Plata. Federico's expertise encompasses translational medicine, neurodevelopment, autism spectrum disorders (ASD), clinical trials, and biomarker research.